24 AFIAS test cassettes for qualitative detection of Creatine Kinase Isoenzyme-MB (CK-MB) in human whole blood, serum or plasma
Package contents:
24 AFIAS test cassettes
24 Pipette tips
1 ID-Chip
1 package insert
Exclusively for professional users
Discover more than 2,000 medical and toxicological tests and POCT solutions
Please note: The prices shown are basic list prices. Your individual prices will be displayed after you have logged in to the shop. Your personal customer advisors can add them at any time.
The AFIAS CK-MB test is a fluorescence Immunoassay (FIA) for the quantitative determination of Creatine Kinase Isoenzyme-MB (CK-MB) in human whole blood/serum/plasma. It is useful as an aid in management and monitoring of acute myocardiac infarction (AMI) and acute coronary syndrome (ACS). For in vitro diagnostic use only.
Creatine kinase (CK), also known as creatine phosphokinase or phospho-creatin kinase, is an enzyme expressed by various tissues and cell types. Disruption of cell membranes due to hypoxia or other injury releases CK from the cellular cytosol into the systemic circulation. CK is a dimeric enzyme consisting of two subunits that can be either B- (brain type) or M- (muscle type). These subunits associate to form three isoforms: CK-BB, CK-MM and CK-MB. These isoenzymes are expressed at different levels in different human tissues. Although CKMM is the most abundant CK isoenzyme in heart muscle, CK-MB accounts for about 20% of total CK in heart muscle tissue. Elevated total CK levels are not specific to myocardial tissue and may be seen in patients with skeletal muscle injury and certain other diseases. Since CK-MB is more specific for myocardial tissue, the CK-MB level, together with the total CK level, can be considered an important diagnostic indicator of myocardial infarction. The concentration of CK-MB in a healthy adult is less than 7.0 ng/mL, but it rises sharply in some malignancies, mainly primary coronary syndrome, myocardial injury and infarction. CK-MB has been found to be more sensitive and an early indicator of myocardial injury because it has a lower basal level and a much narrower normal range. It is often noted in the medical literature that after acute myocardial infarction, CK-MB levels rise 4 to 9 hours after the onset of chest pain, peak at 10 to 24 hours and return to normal within 2 to 3 days. The use of the CK-MB level as a percentage of total CK in the diagnosis of myocardial infarction is the most important clinical application of CK measurements in clinical chemistry.
